TY - JOUR
T1 - Direct reprogramming of induced neural progenitors
T2 - A new promising strategy for AD treatment
AU - Lai, Siqiang
AU - Zhang, Min
AU - Xu, Dongsheng
AU - Zhang, Yiying
AU - Qiu, Lisha
AU - Tian, Changhai
AU - Zheng, Jialin Charlie
N1 - Publisher Copyright:
© Lai et al.; licensee BioMed Central.
PY - 2015/4/18
Y1 - 2015/4/18
N2 - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.
AB - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.
KW - Alzheimer's disease
KW - Induced neural progenitor cells
KW - Stem cell-based therapy
UR - http://www.scopus.com/inward/record.url?scp=84928821804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928821804&partnerID=8YFLogxK
U2 - 10.1186/s40035-015-0028-y
DO - 10.1186/s40035-015-0028-y
M3 - Review article
C2 - 25949812
AN - SCOPUS:84928821804
SN - 2047-9158
VL - 4
JO - Translational Neurodegeneration
JF - Translational Neurodegeneration
IS - 1
M1 - 7
ER -